# Evaluation of the Effect of a Daily Dose of Wakame Seaweed on Reducing Circulating Concentrations of Advanced Glycation End Products in Patients With Stage III Chronic Kidney Disease

> **NCT07729683** · NA · RECRUITING · sponsor: **Groupe Hospitalier de la Rochelle Ré Aunis** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DIETARY_SUPPLEMENT:** Consumption of wakame

## Key facts

- **NCT ID:** NCT07729683
- **Lead sponsor:** Groupe Hospitalier de la Rochelle Ré Aunis
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-27
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729683, "Evaluation of the Effect of a Daily Dose of Wakame Seaweed on Reducing Circulating Concentrations of Advanced Glycation End Products in Patients With Stage III Chronic Kidney Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*